Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) treatment often involves cisplatin and tyrosine kinase inhibitors (TKIs).
• Acquired drug resistance to these therapies significantly reduces their effectiveness in NSCLC patients.
• Developing strategies to overcome drug resistance in NSCLC is a critical unmet medical need.

Purpose of the Study:

• To develop a novel therapeutic strategy to overcome cisplatin and TKI resistance in NSCLC.
• To evaluate the efficacy of a new drug conjugate, DZ-simvastatin (DZ-SIM), in preclinical models of NSCLC.

Main Methods:

• Synthesis of DZ-simvastatin (DZ-SIM), a conjugate of a tumor-homing heptamethine carbocyanine dye (DZ) and simvastatin.
• In vitro evaluation of DZ-SIM against cisplatin-sensitive/resistant and EGFR-TKI-sensitive/resistant NSCLC cell lines.
• In vivo assessment of DZ-SIM efficacy in xenograft models using drug-resistant NSCLC cells.
• Investigation of the mechanism of cell death induced by DZ-SIM.

Main Results:

• DZ-SIM demonstrated potent cytotoxicity against both cisplatin-sensitive and resistant NSCLC cells.
• The conjugate effectively killed EGFR-TKI-sensitive and resistant NSCLC cells.
• DZ-SIM specifically accumulated in and inhibited the growth of xenograft tumors derived from TKI-resistant NSCLC cells.
• DZ-SIM induced cancer cell death by disrupting mitochondrial structure and function.

Conclusions:

• DZ-simvastatin (DZ-SIM) exhibits significant anti-cancer activity against various forms of drug-resistant NSCLC.
• The conjugate's ability to target mitochondrial function presents a novel therapeutic avenue.
• DZ-SIM holds promise as a potential new therapy for overcoming drug resistance in NSCLC patients.